المؤلفون: Antoine Hollebecque, Sonia Extremera, Gilles Salles, Vicente Alfaro, Sandrine Aspeslagh, Mark N. Stein, Emmanuel Gyan, Salvador Fudio, Rastilav Bahleda, Arturo Soto-Matos, Jean-Charles Soria

المساهمون: Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Medical Oncology

المصدر: Anti-Cancer Drugs
Anti-Cancer Drugs, Lippincott, Williams & Wilkins, 2016, ⟨10.1097/CAD.0000000000000457⟩

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Lymphoma, Administration, Oral, Deoxycytidine, Gastroenterology, Depsipeptides/administration & dosage, 0302 clinical medicine, Depsipeptides, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Medicine, Pharmacology (medical), Prospective Studies, Fatigue, Nausea, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, 3. Good health, 030220 oncology & carcinogenesis, Toxicity, Vomiting, young adult, Female, France, medicine.symptom, medicine.drug, Niacinamide, Sorafenib, Adult, medicine.medical_specialty, Patients, [SDV.CAN]Life Sciences [q-bio]/Cancer, Peptides, Cyclic, 03 medical and health sciences, Niacinamide/administration & dosage, Refractory, Internal medicine, Humans, Adverse effect, Deoxycytidine/administration & dosage, Aged, Lymphoma/drug therapy, Pharmacology, therapy, Dose-Response Relationship, Drug, business.industry, Phenylurea Compounds, toxicity, medicine.disease, Gemcitabine, Thrombocytopenia, Neoplasms/drug therapy, SORAFENIB, 030104 developmental biology, Phenylurea Compounds/administration & dosage, Erythema, business, aged, 80 and over

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a23b85d24896c8e6b050b4cfb9ec050cTest
https://hal.archives-ouvertes.fr/hal-01791282Test

المؤلفون: Thomas Hundsberger, Dietrich Py, N. Dunkel, A. Ben Aissa, Maria Vargas, Andreas F. Hottinger, Karl Lothard Schaller, Vittoria Espeli, Nicolas Mach, D. Squiban, Damien C. Weber, A Bodmer

المصدر: British Journal of Cancer, vol. 110, no. 11, pp. 2655-2661
British Journal of Cancer
British Journal of Cancer, Vol. 110, No 11 (2014) pp. 2655-2661

مصطلحات موضوعية: Oncology, Male, Cancer Research, medicine.medical_treatment, Pharmacology, urologic and male genital diseases, radiation therapy, tyrosine kinase inhibitor, Antineoplastic Combined Chemotherapy Protocols, heterocyclic compounds, ddc:616, Glioblastoma/mortality/therapy, Brain Neoplasms, Chemoradiotherapy, Middle Aged, Sorafenib, Brain Neoplasms/mortality/therapy, female genital diseases and pregnancy complications, Phase i study, Dacarbazine, Treatment Outcome, Female, Corrigendum, high-grade glioma, medicine.drug, Adult, Niacinamide, medicine.medical_specialty, Niacinamide/administration & dosage/analogs & derivatives, Maximum Tolerated Dose, ddc:616.0757, pharmacokinetic study, Disease-Free Survival, Glioma, Internal medicine, medicine, Temozolomide, Humans, neoplasms, Aged, business.industry, Phenylurea Compounds, medicine.disease, digestive system diseases, ddc:616.8, First line treatment, Radiation therapy, Phenylurea Compounds/administration & dosage, Clinical Study, Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics/therapeutic use/toxicity, Dacarbazine/administration & dosage/analogs & derivatives, business, Glioblastoma

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5769967950cf20f0072e4f151af7bd83Test
https://serval.unil.ch/resource/serval:BIB_A3EE92645B9C.P001/REF.pdfTest